

## UNITED STATES PATENT AND TRADEMARK OFFICE



APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET.NO.	£
10/007,856	11/05/2001	Thomas P. Stossel	B0801/7232	7592
23628	7590 06/16/2003			
WOLF GREENFIELD & SACKS, PC			EXAMINER	
600 ATLAN	ESERVE PLAZA FIC AVENUE		AFREMOVA, VERA	
BOSTON, MA 02210-2211			ART UNIT	PAPER NUMBER
			1651	
			DATE MAILED: 06/16/2003	3

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No. 10/007,856 Applicant(s)

Stossel et al.

Examiner

Vera Afremova

Art Unit 1651



	The MAILING DATE of this communication appears	on the cover she	et with	the correspondence address	
	for Reply				
	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE	3	MONTH(S) FROM	
mailing	ions of time may be available under the provisions of 37 CFR 1.136 (a). In date of this communication.				•
- If NO p - Failure	period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply a to reply within the set or extended period for reply will, by statute, cause the set or extended period for reply will, by statute, cause the set or extended period for reply will, by statute, cause the set or extended period for reply will, by statute, cause the set or extended period for reply will, by statute, cause the set or extended period for reply will, by statute, cause the set or extended period for reply will, by statute, cause the set or extended period for reply will, by statute, cause the set or extended period for reply will be set or extended period	and will expire SIX (6) In the application to become	MONTHS for ABANDO	om the mailing date of this communication. ONED (35 U.S.C. § 133).	
•	ply received by the Office later than three months after the mailing date of t patent term adjustment. See 37 CFR 1.704(b).	this communication, eve	en if timely	filed, may reduce any	
Status					
1) 💢	Responsive to communication(s) filed on Apr 8, 20	03			
2a) 🗌	This action is <b>FINAL</b> . 2b) 🔀 This act	ion is non-final.			
3) 🗆	Since this application is in condition for allowance closed in accordance with the practice under $Ex\ pa$				
	tion of Claims				
4) 💢	Claim(s) <u>1-4, 13, 15, 35-38, 45, 46, 48, 53-57, 6</u>	7, and 68		is/are pending in the application.	
4	a) Of the above, claim(s) <u>2-4, 13, 15, 35-38, 45, 4</u>	6, 48, 53-57, 6	7, and	68 is/are withdrawn from considerati	on.
5) 🗆	Claim(s)			is/are allowed.	
6) 🗆	Claim(s)	· 		is/are rejected.	
7) 💢	Claim(s) 1	. "		is/are objected to.	
8) 🗆	Claims	are	subject	to restriction and/or election requirement	ent.
Applica	tion Papers				
9) 🗆	The specification is objected to by the Examiner.				
10)	The drawing(s) filed on is/are	a) 🗆 accepted	or b)[	$\square$ objected to by the Examiner.	
	Applicant may not request that any objection to the d	rawing(s) be held	d in abe	yance. See 37 CFR 1.85(a).	
11)	The proposed drawing correction filed on	is:	a)□ a	pproved b) $\square$ disapproved by the Exam	niner.
	If approved, corrected drawings are required in reply	to this Office acti	ion.		
12)	The oath or declaration is objected to by the Exami	iner.			
	under 35 U.S.C. §§ 119 and 120				
_	Acknowledgement is made of a claim for foreign pr	riority under 35	U.S.C.	§ 119(a)-(d) or (f).	
	All b)☐ Some* c)☐ None of:				
	1. Certified copies of the priority documents hav				
	2. U Certified copies of the priority documents hav				
	<ol> <li>Copies of the certified copies of the priority de application from the International Bure se the attached detailed Office action for a list of the</li> </ol>	au (PCT Rule 17	7.2(a)).	•	
_	Acknowledgement is made of a claim for domestic				
	The translation of the foreign language provisional				
15)	Acknowledgement is made of a claim for domestic				
Attachm			3 3.01		
	tice of References Cited (PTO-892)	4) Interview Sum	mary (PTC	-413) Paper No(s)	
2) 💢 No	tice of Draftsperson's Patent Drawing Review (PTO-948)	_		Application (PTO-152)	
3) 💢 Inf	ormation Disclosure Statement(s) (PTO-1449) Paper No(s)6	6) Other:			

Application/Control Number: 10/007,856

Art Unit: 1651

#### **DETAILED ACTION**

#### Election/Restriction

Applicants' election with traverse of Group I (claim 1) in Paper No. 8 filed 4/08/2003 is acknowledged. The traversal is on the ground(s) that the Groups I-IV are drawn to similar methods identifying a platelet clearance antagonist. This is not found persuasive because the claimed methods requires different structural elements as claimed such as chilled platelets, ligands of platelets, liver macrophages and receptors of liver macrophages. Thus, the claimed methods are different and they require different consideration and searches. The requirement is still deemed proper and is therefore made FINAL.

Claims 2-4 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected inventions, there being no allowable generic or linking claim.

Applicant timely traversed the restriction requirement in Paper No. 8.

Claims 13, 15, 35-38, 45, 46, 48, 53-57, 67 and 68 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in Paper No. 8.

Claims 5-12, 14, 16-34, 39-44, 47, 49-52, 58-66 and 69-73 were canceled by applicants in the Paper No. 4 (preliminary amendment) filed 4/05/2001.

Claim 1 is under examination in the instant office action.

Application/Control Number: 10/007,856

Art Unit: 1651

### Claim Objections

Claim 1 is objected to because of the following informalities:

There are some typing error. Appropriate correction is required and it is suggested as follows:

Claim 1, line 2, the phrase "Contacting" should be replaced by ---contacting---.

Claim 1, line 4, the phrase "Detecting" should be replaced by ---detecting---.

Claim 1, line 5, the phrase "Wherein" should be replaced by ---wherein---.

Claim 1 drawn to a method for identifying a platelet clearance antagonist by detecting a reduction in the binding of a chilled platelet to a liver macrophage in the in vitro system in the presence of a test molecule, which is the platelet clearance antagonist, is free from prior art. According to the applicants' definitions a chilled platelet is a platelet exposed to a temperature less than 22°C or about 4 °C (specification page 5, last par.) According to the applicants' definitions liver macrophages are Kupffer cells (specification page 6, line 14) which are obtained from liver (specification page 49, par. 3).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vera Afremova whose telephone number is (703) 308-9351. The examiner can normally be reached on Monday to Friday from 9:00 to 5:30.

Application/Control Number: 10/007,856

Art Unit: 1651

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn, can be reached on (703) 308-4743. The fax phone number for this Group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Vera Afremova

Art Unit 1651

VERA AFREMOVA

June 13, 2003

PATENT EXAMINER

V. Afren